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Abstract
Background: Multiple sclerosis is a demyelinating autoimmune disease, for which
there is no blood-borne biomarker. Erythrocytes may provide a source of such
biomarkers as they contain microRNAs. MicroRNAs regulate protein translation
through complementary binding to messenger RNA. As erythrocytes are transcrip-
tionally inactive, their microRNA profiles may be less susceptible to variation. The
aim of this study was to assess the biomarker potential of erythrocyte microRNAs for
multiple sclerosis and assess the potential contribution of erythrocyte-derived extra-
cellular vesicle microRNAs to pathology.
Methods: Erythrocytes were isolated from whole blood by density gradient centrifu-
gation. Erythrocyte microRNAs of a discovery cohort (23 multiple sclerosis patients
and 22 healthy controls) were sequenced. Increased expression of miR-183 cluster
microRNAs (hsa-miR-96-5p, hsa-miR-182-5p and hsa-miR-183-5p) was validated
in an independent cohort of 42 patients and 45 healthy and pathological (migraine)
Abbreviations: ARCS, audio-recorded cognitive screen; ARMSS, age-related multiple sclerosis severity; AUC, area under the curve; BBB, blood-brain
barrier; cDNA, complementary DNA; CNS, central nervous system; CSF, cerebrospinal fluid; DMT, disease-modifying therapy; DNA, deoxyribonucleic
acid; EAE, experimental autoimmune encephalomyelitis; EDSS, expanded disability status scale; EV, extracellular vesicle; FDR, false discovery rate; GWAS,
genome-wide association study; HC, healthy control; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; miRNA, microRNA; MP, migraine
patient; MRI, magnetic resonance imaging; mRNA, messenger RNA; MS, multiple sclerosis; MSSS, multiple sclerosis severity score; NGS, next-generation
sequencing; NS, not significant; PBMC, peripheral blood mononuclear cell; PPMS, primary progressive multiple sclerosis; RISC, RNA-induced silencing
complex; RNA, ribonucleic acid; ROC, receiver operating characteristic; RRMS, relapsing-remitting multiple sclerosis; RT-qPCR, reverse-transcription
quantitative PCR; SD, standard deviation of the mean; sNfL, serum neurofilament light chain; SNP, single nucleotide polymorphism; SPMS, secondary
progressive multiple sclerosis.
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controls. Erythrocyte-derived extracellular vesicles were created ex vivo and their
microRNAs were sequenced. Targets of microRNAs were predicted using miRDIP.
Results: Hsa-miR-182-5p and hsa-miR-183-5p were able to discriminate relapsing
multiple sclerosis patients from migraine patients and/or healthy controls with 89-
94% accuracy and around 90% specificity. Hsa-miR-182-5p and hsa-miR-183-5p
expression correlated with measures of physical disability and hsa-miR-96-5p expres-
sion correlated with measures of cognitive disability in multiple sclerosis. Erythro-
cytes were found to selectively package microRNAs into extracellular vesicles and 34
microRNAs were found to be differentially packaged between healthy controls and
multiple sclerosis patients. Several gene targets of differentially expressed and pack-
aged erythrocyte microRNAs overlapped with multiple sclerosis susceptibility genes.
Gene enrichment analysis indicated involvement in nervous system development and
histone H3-K27 demethylation.
Conclusions: Erythrocyte miR-183 cluster members may be developed into specific
multiple sclerosis biomarkers that could assist with diagnosis and disability moni-
toring. Erythrocyte and their extracellular microRNAs were shown to target multiple
sclerosis susceptibility genes and may be contributing to the pathophysiology via pre-
viously identified routes.
KEYWORD S
biomarker, erythrocytes, extracellular vesicles, microRNA, multiple sclerosis, next-generation sequencing
1 INTRODUCTION
Multiple sclerosis is an autoimmune disease of the central
nervous system (CNS). In multiple sclerosis, an assumed
lymphocyte-driven pathology causes the destruction of
myelin and neurodegeneration, leading to the formation of
sclerotic plaques.1 Multiple sclerosis affects approximately
2.5 million individuals worldwide,2 but incidence and preva-
lence are rising.3,4
Genetic susceptibility interacting with environmental risk
factors is thought to trigger the onset of multiple sclerosis, yet
the exact cause and detailed pathological mechanisms remain
to be elucidated.1,5 The list of susceptibility genes linked to
multiple sclerosis risk has been growing over the years and
currently includes over 500 potential susceptibility genes and
more than 200 genetic variants identified by several large
genome-wide association studies (GWAS).6 Not one of the
genetic variants is necessary or sufficient for an individual to
develop multiple sclerosis. Therefore, it is likely that several
independent pathological factors lead to multiple sclerosis via
different mechanisms.
Multiple sclerosis comprises three clinical phenotypes:
relapsing-remitting multiple sclerosis (RRMS), secondary
progressive multiple sclerosis (SPMS) and primary progres-
sive multiple sclerosis (PPMS). The majority of patients
(around 85%) are diagnosed with relapse onset multiple scle-
rosis. RRMS patients suffer from transient inflammation-
driven demyelination or relapses.7 Neurodegeneration accu-
mulates due to and independently of relapses.8 While remyeli-
nation of affected areas is possible in early disease, the CNS’
capacity to repair demyelination becomes exhausted over time
and residual relapse disability starts to ensue. This gradual
worsening marks the conversion to the progressive disease
stage. SPMS is considered to be predominantly neurodegen-
erative, though relapses can still occur.7
Key players in multiple sclerosis are peripheral and CNS-
resident immune cells. It is widely accepted that periph-
eral immune cells gain access to the CNS via a damaged
blood-brain barrier (BBB) and initiate the destruction of
myelin by creating an inflammatory environment and acti-
vating microglia.1 Erythrocytes may contribute to multiple
sclerosis pathology through impaired antioxidant capacity and
altered haemorheological features that may facilitate BBB
damage.9 Erythrocytes are anucleate blood cells from the
myeloid lineage that are primarily known for their role in res-
piratory gas transport.10,11 Beyond their role as oxygen and
carbon dioxide carriers, erythrocytes are involved in reducing
oxidative stress and clearing immune complexes.9,12
Current multiple sclerosis diagnosis is based on the exclu-
sion of differentials, such as migraines, neuromyelitis optica
spectrum disorder, infections, malignancy and vasculitis.13
Further, multiple sclerosis diagnoses rely heavily on clinical
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evidence and neurologist expertise. Paraclinical tests that sup-
port such a diagnosis are magnetic resonance imaging (MRI)
of the brain and spinal cord and lumbar punctures to identify
oligoclonal bands in the cerebrospinal fluid (CSF).14 None of
these tests are specific to multiple sclerosis. For instance, non-
specific white matter lesions on MRI scans are also evident in
migraine patients15 and cerebral small vessel disease,16 both
of which are differential diagnoses of multiple sclerosis and
need to be excluded for an accurate diagnosis. This highlights
the need for more specific multiple sclerosis biomarkers to
facilitate diagnostic decision making. To date, there are no
blood-borne biomarkers that are routinely used in clinical set-
tings. Serum neurofilament light chain (sNfL) shows promise
to be developed into a disease activity marker. sNfL is typi-
cally found in the cytoplasm of neurons, but is released into
the CSF in response to neuronal damage. Following release
into the CSF, sNfL is detectable at low concentration in the
serum of multiple sclerosis patients17 using a specialised
detection platform (Simoa).18 While sNfL is a very sensitive
biomarker for multiple sclerosis, it is not specific. Increases
in sNfL can be observed in all instances of CNS damage. For
example, increased sNfL levels could also be detected in fron-
totemporal dementia19 and stroke.20 Therefore, sNfL may be
suitable to detect disease activity multiple sclerosis patients,
who have already been diagnosed, but may not serve as a diag-
nostic test. There is still a need for specific biomarkers to sup-
port multiple sclerosis diagnoses.
MicroRNAs (miRNAs) are small non-coding RNA tran-
scripts that are involved in post-transcriptional regulation of
gene expression and may prove to be specific biomarkers.
In presence of an RNA-induced silencing complex, miR-
NAs can bind to the 3′ untranslated region of messen-
ger RNA (mRNA) transcripts through complementary base
pairing and thereby cause translational repression or tran-
script degradation.21 Some miRNAs are transcribed as clus-
ters or families. These miRNA clusters may target several
genes within the same pathways, enabling increased epige-
netic regulation of these pathways.22 Peripheral miRNAs have
been previously assessed in the context of multiple sclerosis.
However, the findings of previous studies are inconsistent.
Such discrepancies may be attributed to the study of mixed
cell populations, such as peripheral blood mononuclear cells
(PBMCs) or the use of different assays/methods to survey
these miRNAs.23
While human erythrocytes are thought to be translation-
ally inactive,24 they contain abundance of miRNAs.25-27
Erythrocyte miRNAs have been previously implicated in
diseases such as sickle cell disease,26 malaria28 and high
altitude exposure.29 Erythrocytes are abundant in the cir-
culation and can be easily obtained as part of other routine
blood tests, making them a suitable biomarker source.
Further, erythrocytes are a more uniform cell population than
many of the immune cells previously assessed for multiple
sclerosis miRNA biomarkers.23 The lack of transcriptional
activity within erythrocytes hints at a more stable source
of miRNAs.24 Together, this highlights the possibility ery-
throcyte miRNAs have in reducing the variability in miRNA
signatures seen in the literature thus far.
Erythrocyte miRNAs may be left over from erythropoiesis
where they regulate maturation30 or they may be involved
in intercellular communication through extracellular vesicles
(EVs).26,31 EVs are small membrane-bound vesicles that are
released by most cells in response to stress or activation. The
cargo inside these vesicles comprises a number of biologi-
cally active molecules ranging from lipids and carbohydrates
to proteins and nucleic acids. Once released into the extra-
cellular space, EVs can travel to recipient cells and alter the
recipient cells’ state or function through the delivery of their
cargo. Recipient cellsmay take up EVs through endocytosis or
membrane fusion. EVs may also interact with recipient cells
through ligand-receptor binding.32 Research in the malaria
field has shown that erythrocyte miRNAsmay travel to neigh-
bouring recipient cells. EV-delivered miRNAsmay then elicit
changes in gene expression in recipient cells that facilitated
BBB disruption and allowed the parasite to gain access to
the CNS.33 While cerebral malaria and multiple sclerosis are
not directly linked, BBB disruption is characteristic of both.
Hsa-miRNA-451a, which was transferred from erythrocytes
to endothelial cells through EVs, mediated the loss of bar-
rier integrity in cerebral malaria.33 The same miRNA, hsa-
miR-451a, was found at increased levels in multiple sclerosis
patients’ plasma EVs.34 Increased levels of plasma-borne EVs
have been reported in multiple sclerosis and linked to disease
activity.35
Next-generation sequencing (NGS) represents an unbiased
approach to obtain complete miRNA profiles for the identi-
fication of disease-specific signatures. Erythrocyte miRNA
sequencing has been successfully performed by several
research groups.26,27,36 We have previously reported differen-
tial miRNA expression in the erythrocytes of RRMS patients
on various disease-modifying therapies (DMTs).37 The objec-
tive of this study was to assess erythrocyte miRNAs in
untreated multiple sclerosis patients and to determine their
biomarker potential. Additionally, packaging of these miR-
NAs into EVs was assessed to explore the potential function
of erythrocyte miRNAs as intercellular messengers carried by
EVs. This is the first study to investigate erythrocyte-derived
EV miRNAs in multiple sclerosis.
2 MATERIALS AND METHODS
In this case-control study, erythrocyte miRNA expression
was determined by NGS and validated with a targeted
approach and in an independent validation cohort. Diagnos-
tic biomarker potential (multiple sclerosis vs controls) of
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candidate miRNAs was determined through receiver oper-
ating characteristic (ROC) curves. Correlation between ery-
throcyte miRNA expression and disability measures was
assessed to determine the disability biomarker potential.
Finally, erythrocyte-derived EV miRNA levels were mea-
sured to identify whether disease-specific packaging was evi-
dent and targets of differentially expressed and packagedmiR-
NAs were predicted to determine potential involvement in
multiple sclerosis pathogenesis.
2.1 Sample collection
2.1.1 Ethics statement
Ethical approval was obtained from the University of Newcas-
tle (H-505-0607) and the Hunter New England Health Ethics
Committee (2019/ETH12346). Participants were recruited
through the multiple sclerosis clinic at the John Hunter Hospi-
tal, the Hunter Medical Research Institute’s volunteer register
and Dr Andre Loiselle’s migraine clinic (NSW, Australia). In
accordance with the Declaration of Helsinki, all participants
gave written informed consent prior to enrolment.
2.1.2 Inclusion criteria and cohorts
Inclusion criteria for multiple sclerosis patients (cases) were
that they had to (a) be ≥18 years old, (b) meet 2017 McDon-
ald criteria for multiple sclerosis,14 (c) be treatmentnaïve or
off DMT for >6 months prior to sample collection and (d) not
have received corticosteroids in the 90 days prior to sample
collection. Patients were excluded if they had an autoimmune
condition other than multiple sclerosis. Healthy controls
(HC) had to be (a) age-matched to patients (±2 years) and (b)
free of any autoimmune or (c) CNS disease. Migraines are
part of the multiple sclerosis differential, therefore migraine
patients were recruited as pathological controls. Migraine
patients had to be (a) free of autoimmune disease and (b)
CNS disease other than migraines. All participants who
were pregnant or breastfeeding were excluded. To minimise
potential confounders, only females were recruited.
We collected three independent cohorts for this study.
2.1.2.1 Discovery cohort
Sample size was based on power calculations in G*Power
3.1.9. To obtain 90% power at 𝛼 = .05, 12 samples per group
(12 RRMS, 12 SPMS and 24matched controls) were required.
Eleven RRMS patients (stable), 12 SPMS patients and 22 age-
matched HCs were recruited. Patients were considered stable
if they had not presented with any new clinical symptoms or
gadolinium-enhancing lesions on MRI scans in the 120 days
pre-collection and 90 days post-collection.
2.1.2.2 Validation cohort
Eighteen RRMS patients (stable), 14 relapsing patients, 13
SPMS patients, 27 matched HCs and 20 migraine patients
were recruited. Active relapse was defined as new multiple
sclerosis–related symptoms or evidence of gadolinium-
enhancing lesion(s) onMRI scanswithin onemonth of sample
collection. Only patients that had not received corticosteroids
prior to sample collection were included as relapsing
patients.
2.1.2.3 Erythrocyte-derived EV cohort
Twelve stable RRMS patients, seven relapsing patients, eight
SPMS patients and 16 matched HCs were recruited. Three of
the stable RRMS patients, three of the relapsing patients, three
of the SPMS patients and eight of the HCs were also part of
the validation cohort.
Ten millilitres of whole blood were collected into
lithium heparin-coated vacutainers (Vacuette®, Greiner Bio-
One, Kremsmuenster, Austria) via venepuncture. Additional
patient information was obtained through MSBase.38 Age-
related multiple sclerosis severity (ARMSS) scores and mul-
tiple sclerosis severity scores (MSSS) were calculated using
the ms.sev package (v. 1.0.4) in R (v. 3.6.1). Patient demo-
graphics are listed in Table 1.
2.2 Blood processing
Erythrocytes were obtained via differential centrifugation
with density gradient media (Lymphoprep, STEMCELL
Technologies, Vancouver, Canada) as previously described.37
Erythrocyte purity was determined by flow cytometry (FITC-
conjugated anti-CD235a antibody, Clone 2B7, BD Pharmin-
gen, Franklin Lakes NJ, USA) as previously described.37
All samples met a purity cut-off of 95%. Erythrocyte pellets
(300 µL aliquots) were then frozen at −80◦C until RNA was
extracted in batches of 12.
We attempted to isolate erythrocyte-derived EVs from
plasma; however, we were unable to obtain sufficient EVs
of acceptable purity for sequencing. Further, libraries con-
structed from plasma EVs did not pass quality control. There-
fore, erythrocyte-derived EVs were created ex vivo from puri-
fied erythrocytes. For erythrocyte-derived EVs, erythrocytes
were purified as described above from the EV cohort. Five
millilitres of purified erythrocytes were then incubatedwith 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)-
buffered RPMI (Roswell Park Memorial Institute) (Thermo
Fisher Scientific, Waltham MA, USA) media for 24 hours in
37◦C and 5% CO2. Supernatants were harvested via a series
of centrifugation steps (1500 × g for 10 minutes with break
off, followed by 3000 × g for 15 minutes with break twice)
and frozen at −80◦C until RNA was extracted in batches
of 10.
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TABLE 1 Participant demographics
RRMS (stable) Relapse HC (RRMS) SPMS HC (SPMS) Migraine patients
Discovery cohort
N 11 n/a 11 12 11 n/a
Age (years) 49.8 (±12.5) 48.4 (±13.3) 59.5 (±6.7) 61.2 (±7.0)
Disease duration (years) 15.7 (±7.7) n/a 23.0 (±11.6) n/a
Progression duration (years) n/a 7.1 (±6.5)
EDSS score 2.2 (±1.5) 6.3 (±0.9)
Age at onset (years) 34.0 (±12.4) 36.5 (±10.1)
Number of relapses 4 (±2) 5 (±3)
Days since last relapse 1753 (±1825) 3005 (±2545)
Most recent ARCS score
a
98.3 (±16.0) 77.3 (±36.3)
Validation cohort
N 18 14 17 10 8 20
Age (years) 48.0 (±13.9) 37.6 (±9.7) 48.3 (±14.5) 64.0 (±13.9) 64.1 (±11.1) 44.4 (±12.6)
Disease duration (years) 18.3 (±13.9) 4.8 (±8.0) n/a 27.2 (±12.0) n/a n/a
Progression duration (years) n/a n/a 3.2 (±2.6)
EDSS score 1.6 (±1.4) 3.7 (±1.8) 5.7 (±1.7)
Age at onset (years) 29.8 (±10.4) 32.6 (±8.7) 37.2 (±13.8)
Number of relapses 4 (±3) 4 (±5) 3 (±2)
Steroids ≤ 3 months (% yes) 0 28.6 0
Days since last relapse 2491 (±4527) 13 (±15) 4843 (±2782)
Most recent ARCS score
a
90.8 (±10.0) 77.3 (±18.9) 93.8 (±15.9)
Erythrocyte-derived extracellular vesicle cohort
N 12 7 11 8 5 n/a
Age (years) 43.4 (±10.5) 30.2 (±5.9) 43.1 (±11.2) 62.7 (±9.4) 56.4 (±8.0)
Disease duration (years) 6.8 (±6.5) 4.8 (±3.8) n/a 26.9 (±14.2) n/a
Progression duration (years) n/a n/a 13.0 (±17.4)
EDSS score 2.1 (±1.3) 2.7 (±1.5) 5.7 (±2.2)
Age at onset (years) 36.6 (±10.8) 25.3 (±5.4) 29.1 (±15.5)
Number of relapses 4 (±4) 4 (±4) 5 (±4)
Steroids ≤ 3 months (% yes) 0 42.9 0
Days since last relapse 983 (±1178) 9 (±14) 5052 (±5759)
Note. Data shown as mean (±SD).
Abbreviations: ARCS, audio-recorded cognitive screen; EDSS, expanded disability status scale; HC, healthy control; n/a, not applicable; RRMS, relapsing-remitting
multiple sclerosis; SD, standard deviation of the mean; SPMS, secondary progressive multiple sclerosis.
aARCS scores are only reported for patients who performed an ARCS within 12 months of sample collection (n = 31).
2.3 RNA extraction
2.3.1 Erythrocytes
RNA was extracted from erythrocyte pellets with miRNeasy
Mini kits (QIAGEN, Germany) as per manufacturer’s pro-
tocol. Erythrocytes were lysed and homogenised by vortex-
ing samples with QIAzol lysis reagent (QIAGEN, Hilden,
Germany) for 1 minute. RNA concentration was determined
with the Qubit 2.0 fluorometer (Thermo Fisher Scientific,
WalthamMA,USA), using the broad-range RNA assay (Invit-
rogen, Carlsbad CA, USA), and purity was checked on the
Epoch Two microplate spectrophotometer (Millennium Sci-
ence, Mulgrave VIC, Australia).
2.3.2 Erythrocyte-derived EVs
RNA was extracted from 4 mL of erythrocyte super-
natant using ExoRNeasy Serum/Plasma Maxi kits (QIAGEN,
Hilden, Germany), which isolate EVs as part of the RNA
extraction process. RNA concentration was determined with
the Qubit 2.0 fluorometer, using the high-sensitivity RNA
assay (Invitrogen, Carlsbad CA, USA). Due to low yields,
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purity was not checked. A negative control (cell culture
medium only) was also prepared.
RNA samples were frozen at −80◦C until NGS library
preparation or complementary DNA (cDNA) synthesis for
reverse-transcription quantitative PCR (RT-qPCR).
2.4 Next-generation sequencing
2.4.1 Erythrocyte RNA
RNA from the discovery cohort was subjected to NGS on a
MiSeq (Illumina, San Diego CA, USA) platform. Small RNA
library preparation was performed using the TruSeq small
RNA library preparation kits (Illumina, San Diego CA, USA).
Libraries were pooled and run on an agarose gel for size exclu-
sion prior to being purified with the Wizard SV Gel and PCR
Clean-Up system (Promega,MadisonWI, USA). Quality con-
trol of NGS libraries was performed on the Tape Station (Agi-
lent Technologies, Santa Clara CA, USA). Libraries were
sequenced on four different flow cells for 37 cycles (MiSeq
reagent kit v2, 50 cycles; Illumina, San Diego CA, USA) in a
single-end fashion, aiming for one million reads per sample.
2.4.2 Erythrocyte-derived EV RNA
RNA from the EV cohort and the negative control (RNA
extraction from culture medium) were subjected to library
preparation. MicroRNA libraries were created with the
QIAseq miRNA library kit (QIAGEN, Hilden, Germany).
This kit was chosen over the Illumina library preparation kit,
as its input requirement was lower and could accommodate
the low RNA yields from erythrocyte-derived EVs. Libraries
were pooled and sequenced in single-end fashion on a
NextSeq 500 flow cell (NextSeq 500/550 High Output v2.5
kit , 150 cycles; Illumina, San Diego CA, USA).
2.5 Reverse-transcription quantitative PCR
Samples from the discovery and the validation cohort (includ-
ing samples that did not pass quality control in the discovery
cohort) were subjected to cDNA synthesis for RT-qPCR. The
commercially available TaqMan Advanced cDNA synthesis
kit (Thermo Fischer Scientific, WalthamMA, USA) was used
for cDNA synthesis. RNA input was 10 ng at 5 ng/µL. Quan-
titative PCR assays were performed using TaqMan Advanced
miRNA probes (Thermo Fischer Scientific, Waltham MA,
USA). The following probes were used: hsa-miR-96-5p
(478215_mir), hsa-miR-18a-5p (478551_mir), hsa-let-7i-5p
(478375_mir), hsa-miR-183-5p (477937_mir), hsa-miR-
30a-5p (479448_mir), hsa-miR-106b-3p (477866_mir), hsa-
miR-191-5p (477952_mir), hsa-miR-103a-3p (478253_mir),
hsa-miR-629-5p (478183_mir), hsa-miR-30e-3p
(478388_mir), hsa-miR-1307-3p (483036_mir), hsa-
miR-1246 (477881_mir) and hsa-miR-182-5p (477935_mir).
Hsa-miR-152-3p (477921_mir) was used as an endogenous
control.26,37 All qPCR plates included no template controls,
RNA controls and no reverse-transcriptase controls. Relative
expression was calculated using the 2−(Ct miRNA of interest – Ct
hsa-miR-152-3p) method.
2.6 Target prediction and gene enrichment
analysis
Targets of differentially expressed and packaged miRNAs
were predicted using miRDIP 4.1, an integrative online
database.39 Only targets that met the score class ‘Very High
(Top 1%)’ were included. Gene enrichment analysis of tar-
gets was performed using GO Enrichment Analysis.40 Multi-
ple sclerosis susceptibility genes were taken from the Interna-
tional Multiple Sclerosis Genetics Consortium GWAS (Table
S19).6 Duplicate susceptibility genes were removed prior to
analysis.
2.7 Statistical analysis
2.7.1 Sequencing data
Data was analysed as described by Cordero et al.41 Briefly,
adapters were trimmed with cutadapt. Sequencing reads were
aligned against miRNAs deposited in miRBase (v. 22) with
SHiMPS aligner and differential expression was computed in
DESeq2. QIAGENuniquemolecular identifiers were not used
to allow erythrocyte and erythrocyte-derived EV miRNA
counts to be analysed together. Samples that did not pass qual-
ity control due to low reads were excluded prior to analysis.
MicroRNAswith less than 10 reads (average) per sample were
excluded prior to running DESeq2 (run in R v. 3.6.1). MicroR-
NAs with fold changes of ≥2 or ≤0.5 were considered differ-
entially expressed between groups. Log fold change shrinkage
was performed using the ‘apeglm’ package within DESeq2.
2.7.2 RT-qPCR
Statistical analysis was performed in R v. 3.6.1 and differen-
tial expressionwas determined throughKolmogorov-Smirnov
tests. A P-value of less than .05 was deemed statistically
significant.
2.7.3 Biomarker analysis
ROC curve analysis was carried out in R v. 3.6.1. Accu-
racy was estimated using area under the curve (AUC) and
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thresholds that maximised both sensitivity and specificity
were chosen; 95% CI intervals were reported. Correla-
tions between the expression of different miRNAs were
determined using Pearson’s correlation coefficients, and
correlations between miRNA expression and other clinical
parameters were determined using Spearman’s rho based
on distribution of the data and the relationship between the
variables. P-values were corrected for multiple testing using
the Benjamini-Hochberg method.
3 RESULTS
As erythrocyte miRNAs are not well characterised and to
eliminate potential confounders associated with sex in the
small cohorts of this study, only female participants were
recruited and controls were age-matched (±2 years). Patient
demographics are summarised in Table 1. Erythrocyte purity
was determined by flow cytometry as previously described.37
Mean erythrocyte purity across all samples was 96.08%.
The average RNA yield per 300 µL erythrocyte pellet was
1589.4 ng (±826.1 ng).
3.1 Next-generation sequencing of
erythrocyte microRNAs (discovery cohort)
The discovery cohort was used for NGS. NGS runs yielded
between 12 170 404 and 13 459 251 reads with more than
95% of base calling scores ≥Q30 across all runs. More than
97% of reads could be aligned to mature miRNAs deposited in
miRBase (v. 22) across all four runs. Two RRMS samples and
one SPMS sample were removed from the discovery cohort
prior to analysis due to low reads. Their matched HCs were
also removed.
NGS detected differential erythrocyte miRNA expression
in multiple sclerosis patients compared to HCs (Support-
ing Information File 1). Ten miRNAs were differentially
expressed in multiple sclerosis patient erythrocytes (RRMS
and SPMS combined, n = 20) compared to HCs (n = 18).
Four of these showed decreased expression in multiple sclero-
sis. Of the differentially expressedmiRNAs, hsa-miR-183-5p,
hsa-miR-30a-5p, hsa-miR-191-5p, hsa-miR-18a-5p, hsa-let-
7i-5p, hsa-miR-106b-3p and hsa-miR-1307-3p were chosen
for validation based on significance.
Looking at multiple sclerosis disease courses individu-
ally, five erythrocyte miRNAs showed decreased and seven
increased expression in stable RRMS (n = 9) compared to
HCs (n = 9). As expected, many of these overlapped with dif-
ferentially expressed miRNAs identified in the multiple scle-
rosis versus HC comparison. In addition to the miRNAs listed
above, hsa-miR-629-5p, hsa-miR-30e-3p, hsa-miR-103a-3p
and hsa-miR-1246 were also chosen for validation. Addition-
ally, hsa-miR-96-5p, which was differentially expressed in
RRMS patients compared to HCs, was also included in the
targeted assay as it was identified in the discovery phase of
our previous erythrocyte miRNA study.37
Hsa-miR-183-5p showed decreased expression in SPMS
(n = 11) compared to HCs (n = 9) and hsa-miR-30a-5p
showed decreased expression in SPMS compared to RRMS
in a direct comparison.
3.2 Reverse-transcription qPCR of
erythrocyte microRNAs (discovery cohort)
Reverse-transcription qPCR is a less sensitive method than
NGS and significance threshold was not reached for any
candidate miRNA using this method. However, differential
expression trends were confirmed for hsa-miR-18a-5p, hsa-
miR-96-5p and hsa-miR-183-5p. Hsa-miR-1246 could not be
detected by RT-qPCR and was not included in further anal-
yses (PCR efficiencies are shown in Supporting Information
File 2).
3.3 Validation study of erythrocyte
microRNAs (independent validation cohort)
To further validate NGS results, expression of hsa-miR-
18a-5p, hsa-miR-96-5p and hsa-miR-183-5p was assessed in
an independent validation cohort. Hsa-miR-183-5p and hsa-
miR-96-5p are part of the three-member miR-183 cluster.22
Because miRNA clusters tend to be transcribed together, it
was reasoned that the third cluster member, hsa-miR-182-5p,
may also show altered expression. Therefore, hsa-miR-182-
5p was included in the validation study. Samples that were
not included in the discovery cohort analysis due to low-
sequencing reads were included in the validation cohort.
MiR-183 cluster members were expressed in coordinated
fashion. Relative expression of all three miR-183 cluster
members correlated with each other in the different groups
(HCs, migraine patients, stable RRMS patients, relapsing
patients and SPMS patients), and overall in the combined dis-
covery and validation cohort (Figure 1A-C). The correlation
appeared strongest between hsa-miR-182-5p and hsa-miR-
183-5p, which were found to be expressed at similar levels in
erythrocytes. Expression of hsa-miR-96-5p was much lower
in all the groups (Figure 1).
MiR-183 cluster members showed increased expression
during relapse. In relapsing patients, both hsa-miR-183-5p
and hsa-miR-182-5p showed increased expression (P < .001)
compared to stable RRMS patients (hsa-miR-183-5p: 3.15-
fold; hsa-miR-182-5p: 2.44-fold), SPMS patients (hsa-miR-
183-5p: 3.77-fold; hsa-miR-182-5p: 2.80-fold), HCs (hsa-
miR-183-5p: 5.22-fold; hsa-miR-182-5p: 3.46-fold) and
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F IGURE 1 Relative expression (2−deltaCt) of miR-183 cluster members in erythrocytes. A-C, Discovery and validation cohort. Correlation
between the expression of (A) hsa-miR-96-5p and hsa-miR-182-5p, (B) hsa-miR-96-5p and hsa-miR-183-5p and (C) hsa-miR-183-5p and
hsa-miR-182-5p in the different groups (HC: light blue, n = 45; MP: dark blue, n = 20; relapse: orange, n = 14; RRMS: dark green, n = 27; SPMS:
light green, n = 21) and overall (black line). Pearson’s correlation coefficients are shown on the side. D-F, Validation cohort only. Relative expression
of (D) hsa-miR-183-5p, (E) hsa-miR-182-5p and (F) hsa-miR-96-5p is shown in SPMS patients (n = 10, SPMS, light green), stable RRMS patients
(n = 18, RRMS, dark green), relapsing patients (n = 14, relapse, orange), migraine patients (n = 20, MP, dark blue) and HCs (n = 25, HC, light blue).
White circles represent outliers defined as deviating ≥1.5-fold from the upper/lower quartile. HC, healthy control; MP, migraine patient; RE, relative
expression; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis; ***P < .001; ** P < .01; *P < .05
migraine patients (hsa-miR-183-5p: 3.15-fold; hsa-miR-182-
5p: 2.83-fold). Additionally, multiple sclerosis patients’ (sta-
ble RRMS and SPMS combined, n = 28) erythrocytes
harboured increased levels of hsa-miR-182-5p (1.36-fold,
P < .01) compared to HCs (n = 25). Stable RRMS patients
had higher expression of hsa-miR-182-5p compared to HCs
(1.44-fold, P < .01). While hsa-miR-96-5p displayed trends
of increased expression during relapse compared to all other
groups, this trend was only significant when compared to
migraine patients (1.29-fold, P < .05) (Figure 1D-F).
Hsa-miR-18a-5p was not found to be differentially
expressed in the validation cohort (data not shown).
3.4 Biomarker potential and correlations
with clinical data
Biomarker potential and correlations between miRNA-183
cluster members and other clinical measures were assessed
using the combined relative expression data (RT-qPCR) from
the discovery and validation cohort.
Hsa-miR-182-5p and hsa-miR-183-5p showed biomarker
potential for relapsing multiple sclerosis patients. To deter-
mine the biomarker potential of erythrocyte-derived miR-183
cluster expression, ROC curve analysis was carried out. Both
hsa-miR-182-5p and hsa-miR-183-5p showed potential to
distinguish relapsing multiple sclerosis patients (n = 14) from
the combined control groups (HCs and migraine patients,
n= 65), as well as HCs (n= 45) andmigraine patients (n= 20)
independently. Accuracy was estimated using AUC and lay
between 89.6% and 94.3% for the different comparators. Fur-
ther, when choosing threshold values that allowed for optimal
sensitivity and specificity, both miRNAs could exclude
migraine patients with 90% specificity (Figure 2, Table 2).
Combining the two miRNAs in a logistic regression model
did not improve sensitivity, specificity or accuracy (data not
shown).
MicroRNA-183 cluster members correlated with measures
of physical and cognitive disability in multiple sclerosis
(Figure 3, Table 3). In all RRMS patients (stable and
relapsing, n = 41), both hsa-miR-182-5p and hsa-miR-
183-5p expression were positively correlated with expanded
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F IGURE 2 Receiver operating characteristics curves for
hsa-miR-182-5p and hsa-miR-183-5p. Receiver operating characteristic
curves show sensitivity and specificity (reverse axis) in distinguishing
relapsing multiple sclerosis patients (n = 14) from all controls (HC and
MP; n = 65; solid line), from HCs only (n = 45; dashed line) and from
migraine patients only (n = 20; dotted line). Curves associated with
hsa-miR-182-5p are shown in blue and light blue, and curves associated
with hsa-miR-183-5p are shown in green and light green. HC, healthy
control; MP, migraine patient
TABLE 2 Receiver operating characteristic curve values
hsa-miR-182-5p vs hsa-miR-183-5p vs
Relapse
All
controls HC MP
All
controls HC MP
AUC 0.930 0.943 0.900 0.921 0.932 0.896
AUC95% CI 0.842-1 0.849-1 0.784-1 0.831-1 0.839-1 0.779-1
Threshold
a
43.226 51.972 43.078 68.275 68.275 59.417
Sensitivity 0.929 0.857 0.929 0.857 0.857 0.857
Specificity 0.892 0.978 0.900 0.954 0.978 0.900
Abbreviations: AUC, area under the curve; CI, confidence interval; HC, healthy
control; MP, migraine patient.
aThresholds that maximised both sensitivity and specificity are shown.
disability status scale (EDSS) scores, ARMSS scores and
MSSS. Furthermore, expression of hsa-miR-182-5p and hsa-
miR-183-5p decreased with increasing time since patients’
last relapse and showed trends of decreasing expression with
increasing disease duration. However, the lattermay be related
to a reduction in recent relapses in patients with longer disease
duration (Figure 3A, Table 3). Beyond the domain of physi-
cal disability reflected by EDSS and related scores, multiple
sclerosis patients suffer from cognitive disability. One way
of assessing cognitive disability are cognitive screening tests,
such as the audio-recorded cognitive screen (ARCS).42 In
all multiple sclerosis patients [SPMS and RRMS (stable and
relapsing)] who had performed an ARCS within 12 months
of sample collection (n = 31), hsa-miR-96-5p was positively
correlated with patients’ total ARCS score, as well as fluency,
one of the ARCS’ subdomains. Trends of increasing expres-
sion with increasing score in the other subdomains (memory,
visuospatial, language, attention and speed of writing) were
also observed (Figure 3B, Table 3).
3.5 Erythrocyte-derived EV microRNAs
Human erythrocytes are translationally inactive.24 Therefore,
the role of miRNAs within them remains to be elucidated.
One hypothesis is that erythrocyte miRNAs may be packaged
into EVs and travel to translationally active recipient cells
to carry out their function.26,33 As there was an increase in
erythrocyte-derived EVs in the plasma of relapsing multiple
sclerosis patients (Supporting Information File 3), we wanted
to determine whether erythrocytes may be packaging their
miRNAs into EVs in a disease-specific manner in multiple
sclerosis. Therefore, erythrocyte-derived EVs were collected
from the supernatant of incubated erythrocytes. Total RNA
was extracted and small RNA libraries sequenced.
Sequencing of erythrocyte-derived EV miRNAs yielded
between three and nine million reads per sample with 96.01%
of base calling scores ≥Q30. Around 20% of all sample reads
were mappable to miRNAs deposited in miRBase (v. 22.0).
Only 0.6% of the negative control reads were mappable.
Erythrocyte-derived EV miRNAs were selectively pack-
aged. The majority of highly expressed erythrocyte miR-
NAs were also highly enriched in erythrocyte-derived EVs.
However, hsa-miR-486-5p (P = 4.58E-125), hsa-miR-451a
(P = 8.00E-49) and hsa-miR-92-3p (P = 6.25E-76) showed
decreased levels in EVs compared to erythrocytes, and hsa-
miR-223-5p (P ˂ 2.225074E-308), hsa-let-7a-5p (P = 2.89E-
42), hsa-let-7b-5p (P = 5.15E-154) and hsa-miR-142-3p
(P ˂ 2.225074E-308) showed increased levels in EVs com-
pared to erythrocytes (Figure 4A).
Erythrocyte-derived EV miRNAs showed differential
enrichment between multiple sclerosis patients and HCs.
There were 34 differentially enriched erythrocyte-derived EV
miRNAs betweenmultiple sclerosis patients (n= 26) andHCs
(n = 16). Three of these miRNAs were increased in multiple
sclerosis patients compared to HCs. Additionally, there were
17 differentially enriched erythrocyte-derived EV miRNAs
between stable RRMS patients and HCs, 15 between SPMS
patients and HCs, and 36 between relapsing patients and
HCs. Hsa-miR-148-5p was increased in relapsing patients’
EVs compared to stable RRMS patients’ (fold change: 2.62,
P = .003). No differences in EV miRNAs were observed
between SPMS and stable RRMS patients or SPMS patients
and relapsing patients (Figure 4B-E, Supporting Information
File 5). The miR-183 cluster was not found to be differentially
packaged into erythrocyte-derived EVs in multiple sclerosis.
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F IGURE 3 Spearman’s rho correlation matrix of miR-183 cluster members and clinical measures. A, Correlation matrix of miR-183 cluster
member expression, age, EDSS scores, ARMSS scores, MSSS, disease duration and days since last relapse for all RRMS patients (stable and
relapsing, n = 41). B, Correlation between hsa-miR-96-5p expression and ARCS, its subdomain scores (memory, fluency, visuospatial, language,
attention, speed of writing), EDSS scores and disease duration for all multiple sclerosis patients who have undertaken an ARCS within 12 months of
sample collection (n = 31). Positive correlations are shown in blue and negative correlations in red. Nonsignificant correlations are crossed out
(P-values adjusted using Benjamini-Hochberg method; 𝛼 =.05). Quick ARCS scores are ARCS scores that have not been adjusted for education and
age. ARCS, audio-recorded cognitive screen; ARMSS, age-related multiple sclerosis severity; d_since_relapse, days since last relapse; DD, disease
duration; EDSS, expanded disability status scale; MS, multiple sclerosis; MSSS, multiple sclerosis severity score; RRMS, relapsing-remitting
multiple sclerosis; SPMS, secondary progressive multiple sclerosis
TABLE 3 Spearman’s rho of correlations with clinical parameters
hsa-miR-182-5p hsa-miR-183-5p
Spearman’s rho Adj. P-value Spearman’s rho Adj. P-value
EDSS score
a
0.552 .012 0.565 9.0E-03
ARMSS score 0.676 2.0E-04 0.701 4.6E-05
MSSS 0.659 3.0E-04 0.733 8.1E-06
Days since relapse −0.609 8.0E-04 −0.642 2.1E-04
hsa-miR-96-5p
Spearman’s rho Adj. P-value
Total ARCS score
b
0.465 .024
Quick ARCS score 0.466 .024
Subdomain scores Memory 0.362 .117
Fluency 0.548 .004
Visuospatial 0.342 .143
Language 0.261 .323
Attention 0.243 .055
Speed of writing 0.417 .011
a)Data shown for RRMS patients (stable and relapse; n = 41).
b) Data shown for all multiple sclerosis patients whohave undertaken an ARCS within 12 months of sample collection (n = 31).
Abbreviation: ARMSS, age-related multiple sclerosis severity; ARCS, audio-recorded cognitive screen. EDSS, expanded disability status scale; MSSS, multiple sclerosis
severity score; RRMS, relapsing-remitting multiple sclerosis.
3.6 MicroRNA target prediction and gene
enrichment analysis
To assess the potential function of erythrocyte miRNAs and
erythrocyte-derived EV miRNAs in multiple sclerosis, tar-
gets of differentially expressed and packaged miRNAs (mul-
tiple sclerosis versus HCs) were predicted using an online
database.39 Figure 5A-C and Supporting Information File 5
show the targets shared by multiple miRNAs. Multiple miR-
NAs targeting the same transcript may amplify the effects of
post-transcriptional regulation.
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F IGURE 5 Predicted targets of differentially expressed and packaged (extracellular vesicle) erythrocyte microRNAs. A-C, Predicted targets
(yellow circles) of (A) the miR-183 cluster, (B) miRNAs that were increased in multiple sclerosis erythrocyte-derived EVs compared to HCs and (C)
miRNAs that were decreased in multiple sclerosis erythrocyte-derived EVs compared to HCs (red circles). D, Overlap between predicted miRNA
targets for all three groups (A-C) and multiple sclerosis susceptibility genes. Detailed information is provided in Supporting Information File 5. EV,
extracellular vesicle; HC, healthy control; miRNA, microRNA; MS, multiple sclerosis
Several of the miRNA gene targets have been previ-
ously flagged as multiple sclerosis susceptibility genes. Using
the multiple sclerosis susceptibility gene list from the 2019
GWAS,6 miRNA targets that have already been linked to mul-
tiple sclerosis were identified. Of the predicted targets for
the miR-183 cluster and differentially enriched erythrocyte-
derived EV miRNAs, 131 overlapped with the proposed mul-
tiple sclerosis susceptibility genes (Figure 5D, Supporting
Information File 5).
Additionally, gene enrichment analysis was carried out
on the targets of differentially enriched erythrocyte-derived
EV miRNAs. MicroRNAs that were decreased in multiple
sclerosis patients compared to HCs were enriched in sev-
eral pathways linked to nervous system development and his-
tone H3-K27 demethylation (7.9-fold enrichment, P = .041).
MicroRNAs that were increased in multiple sclerosis patients
erythrocyte-derived EVs were enriched in pathways associ-
ated with cardiac muscle contraction (Table 4).
4 DISCUSSION
In this study, erythrocyte miRNAs and erythrocyte-derived
EV miRNAs were predicted to target genes previously impli-
cated in multiple sclerosis susceptibility. This finding high-
lights that erythrocyte miRNAs are reflective of multiple scle-
rosis pathophysiology. Further, erythrocyte miRNAs show
multiple sclerosis–specific biomarker potential that may assist
in ruling out differential diagnoses and monitor disability.
4.1 Erythrocyte microRNAs as biomarkers
Multiple sclerosis diagnosis is currently based on the exclu-
sion of other differentials, which often leaves significant
uncertainty. Consequently, more objective biomarkers are
needed to aid diagnostic decisions, which may lead to earlier
treatment initiation.43 The importance of the latter in reduc-
ing the disability burden in multiple sclerosis has been shown
by numerous studies.43,44 While several attempts to develop
leukocyte miRNA biomarkers for multiple sclerosis can be
found in the literature, the results of these studies are highly
inconsistent.23,45 This may be a result of post-collection
induction of miRNAs in nucleated cells, the use of different
assays or even heterogeneity of the disease. Erythrocytes may
overcome one of these barriers to biomarker development.
Being transcriptionally inactive,24 their miRNA profiles may
be more stable. In fact, evidence for erythrocyte miRNA sta-
bility can be found in the literature.46 To determine biomarker
specificity, a cohort of migraine patients was included in this
study. Similar to multiple sclerosis patients, migraine patients
may present with white matter lesions on MRI scans.15 As
86 GROEN ET AL.
TABLE 4 Gene enrichment analysis of erythrocyte-derived extracellular vesicle microRNA targets
Pathway
Fold
enrichment P-value
FDR-adj.
P-value
Erythrocyte-derived EV microRNAs (decreased in MS compared to HC)
Glossopharyngeal nerve development (GO:0021563) 7.9 2.77E-03 4.13E-02
Histone H3-K27 demethylation (GO:0071557) 7.9 2.77E-03 4.12E-02
Noradrenergic neuron differentiation (GO:0003357) 6.77 1.71E-03 2.81E-02
Maintenance of postsynaptic specialization structure (GO:0098880) 5.92 2.70E-03 4.04E-02
Ventricular compact myocardium morphogenesis (GO:0003223) 5.92 2.70E-03 4.04E-02
Insulin-like growth factor receptor signalling pathway (GO:0048009) 5.64 1.40E-04 3.33E-03
Commissural neuron axon guidance (GO:0071679) 5.26 9.12E-04 1.64E-02
Peripheral nervous system neuron development (GO:0048935) 5.26 9.12E-04 1.64E-02
Peripheral nervous system neuron differentiation (GO:0048934) 5.26 9.12E-04 1.64E-02
Erythrocyte-derived EV microRNAs (increased in MS compared to HC)
AV node cell to bundle of His cell communication (GO:0086067) 5.99 1.03E-03 2.98E-02
Membrane depolarization during cardiac muscle cell action potential (GO:0086012) 5.53 6.38E-05 2.80E-03
Neuromuscular process controlling posture (GO:0050884) 4.53 8.85E-04 2.63E-02
Negative regulation of smooth muscle cell differentiation (GO:0051151) 4.53 8.85E-04 2.63E-02
Hippo signalling (GO:0035329) 4.12 1.39E-04 5.51E-03
Regulation of smooth muscle cell differentiation (GO:0051150) 3.74 1.72E-04 6.61E-03
Membrane depolarization during action potential (GO:0086010) 3.71 3.13E-04 1.12E-02
Regulation of heart rate by cardiac conduction (GO:0086091) 3.6 8.61E-05 3.62E-03
Cell-cell signalling involved in cardiac conduction (GO:0086019) 3.48 1.33E-03 3.71E-02
mRNA destabilization (GO:0061157) 3.42 9.28E-04 2.74E-02
Abbreviations: EV, extracellular vesicle; FDR-adj., false discovery rate-adjusted; HC, healthy control; MS, multiple sclerosis.
a result, migraines are part of the differential diagnoses that
need to be considered in multiple sclerosis. Erythrocyte hsa-
miR-182-5p and hsa-miR-183-5p showed increased expres-
sion during relapse compared to stable RRMS, SPMS, HCs
andmigraine patients (Figure 1). Differences in hsa-miR-182-
5p and hsa-miR-183-5p expression were able to differentiate
relapsing multiple sclerosis patients from HCs and migraine
patients with 92.1% and 93.0% accuracy, respectively, and
89.2% and 95.4% specificity, respectively (Figure 2, Table 2).
Additionally, hsa-miR-183-5p and hsa-miR-182-5p expres-
sion correlated with EDSS scores and related measures of
physical disability. Hsa-miR-96-5p, the third member of the
miR-183 cluster, correlated with cognitive disability (deter-
mined by ARCS; Figure 3, Table 3). This strongly indicates
the diagnostic and disability biomarker potential of these
miRNAs for multiple sclerosis, which may be used in com-
bination with current MRI biomarkers. Increased miR-183
cluster expression has been observed in systemic lupus ery-
thematosus murine model lymphocytes,47 in osteoblasts of
rheumatoid arthritis patients48 and multiple sclerosis murine
model Th17-lymphocytes.49 With erythrocyte miRNA
investigations still in their infancy, future studies should aim
to investigate the expression of miR-183 cluster miRNAs
in the erythrocytes of patients with other autoimmune
diseases.
Although the miR-183 cluster is transcribed as one pri-
mary miRNA,22 there appeared to be differences in expres-
sion between hsa-miR-96-5p and the other two members of
the miR-183 cluster (hsa-miR-182-5p and hsa-miR-183-5p)
(Figure 1). There were also differences in the association with
disability domains (Figure 3, Table 3) between the miRNAs.
This might indicate a difference in function between hsa-
miR-96-5p and the remaining two members of the miR-183
cluster. This hypothesis is further supported by the correla-
tion of both hsa-miR-182-5p and hsa-miR-183-5p with recent
relapses and the absence of this correlation when looking
at expression of hsa-miR-96-5p (Figure 3), a miRNA previ-
ously linked to remission in multiple sclerosis.50 Differences
in expression levels betweenmembers of the same cluster may
indicate alterations in miRNAs post-transcriptionally.22
The entire miR-183 cluster has been previously impli-
cated in multiple sclerosis. In experimental autoimmune
encephalomyelitis, an MS mouse model, enhanced expres-
sion of the miR-183 cluster in Th17-lymphocytes increased
the lymphocytes’ production of pathogenic cytokines and
autoimmunity through the repression of FOXO1.49 While this
link requires confirmation in human samples, hsa-miR-182-
5p was found to be upregulated in the whole blood of pae-
diatric multiple sclerosis patients.51 Elevations of hsa-miR-
96-5p were also previously observed in remitting multiple
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sclerosis patient sera50 and PBMCs.52 Differential expression
of miR-183 cluster miRNAs has not been observed in other
leukocytes in multiple sclerosis.23
While we did not observe the same subset of differentially
expressed erythrocyte miRNAs as in our pilot study, this may
be due to cohort differences. The cohort of the small pilot
study consisted of stable RRMS patients who were on DMT
(predominantly fingolimod or natalizumab).37 In contrast, the
greatest differences in erythrocyte miRNA expression in this
cohort were observed in relapsing multiple sclerosis patients,
and all multiple sclerosis patients were either treatment naïve
or had not received DMT in the 6 months prior to sample col-
lection. Both natalizumab53-55 and fingolimod56 have been
reported to affect erythrocytes. Hence, previously reported
erythrocyte miRNAs37 may reflect treatment effects.
4.2 Potential function of erythrocyte
microRNAs
Erythrocyte miRNAs may represent remnants of the precur-
sor transcriptome or they may be involved in intercellular
communication through EVs. Having observed an increase in
plasma-borne erythrocyte-derived EVs during relapse (Sup-
porting Information File 3), we wanted to investigate the latter
of the two hypotheses.
Sequencing of erythrocyte-derived EV miRNAs revealed
that miRNAs were selectively packaged into EVs (Figure 4).
Selective packaging of EVs in healthy and diseased (can-
cer) cells ex vivo has also been demonstrated in other cell
types.32 Further, erythrocyte-derived EV miRNAs demon-
strated differential enrichment patterns betweenmultiple scle-
rosis patients and HCs (Figure 4).
Target genes of miRNAs that were differentially enriched
in multiple sclerosis patient EVs compared to those of HCs
overlapped with proposed multiple sclerosis susceptibility
genes6 (Figure 5, Supporting Information File 5). None of
the variants, which these susceptibility genes are based on,
are sufficient or necessary for the development of multi-
ple sclerosis. Hence, miRNAs may work in concert with
single nucleotide polymorphisms (SNPs) to alter expres-
sion of susceptibility genes. Increased expression of hsa-
miR-146a, which was enriched in multiple sclerosis patients’
erythrocyte-derived EVs (Figure 4, Supporting Information
File 4), has been linked to the C allele of rs2910164. This SNP
was significantly associated with multiple sclerosis risk.57
Hsa-miR-146a plays a crucial role in mediating immune
responses and inflammation through negative regulation of
Toll-like receptors and inflammatory cytokines.58 Increased
expression of hsa-miR-146a has also been observed in multi-
ple sclerosis patient PBMCs.59 Taken together, these results
strongly implicate hsa-miR-146a inmultiple sclerosis risk and
pathology.
Several other differentially enriched erythrocyte-derived
EV miRNAs (Figure 4, Supporting Information File 4) have
previously been linked to multiple sclerosis. In serum, where
blood cell–derived EVs are numerous,60 and within circulat-
ing EVs, hsa-miR-375,61,62 hsa-miR-342-3p, hsa-miR-374a-
5p,34 hsa-miR-32-3p, hsa-miR-331-3p and hsa-miR-19a-3p61
were identified as differentially enriched in multiple sclerosis.
These reports support that what was observed in our ex vivo
created erythrocyte-derived EVs may also occur in vivo.
Erythrocyte-derived EV hsa-miR-150-5p was enriched in
multiple sclerosis patients compared to HCs (Figure 4, Sup-
porting Information File 4). Similar trends have been observed
in the CSF of patients.63 With erythrocyte-derived EVs being
able to cross the BBB,64,65 miRNAs within them may con-
tribute to CNS pathology. In fact, silencing or reduction
of multiple sclerosis–enriched hsa-miR-150-5p ameliorates
experimental autoimmune encephalomyelitis (EAE), a mul-
tiple sclerosis mouse model.66,67 Further, many of the dif-
ferentially enriched erythrocyte-derived EV miRNAs found
in serum (hsa-miR-375, hsa-miR-32-3p, hsa-miR-331-3p and
hsa-miR-19a-3p) correlated with brain lesions and atrophy.61
Targets of differentially enriched erythrocyte-derived EV
miRNAs were found to be involved in several developmen-
tal pathways of the nervous system as well as histone H3-
K27 demethylation (Table 4). MicroRNAs targeting genes
involved in histone H3-K27 demethylation were found to be
reduced inmultiple sclerosis patient erythrocyte-derived EVs.
Hence, there may be less translational inhibition of the genes
involved in the demethylation pathway and consequently less
methylation at lysine 27 of histone H3. This demethylated
state of the histone protein facilitates access to the gene pro-
moter region and thereby allows transcription of nearby genes.
Acetylation of the same lysine residue has further been shown
to enhance gene transcription.68 These epigenetic mecha-
nisms have been implicated in Th17 differentiation69 and
macrophage phenotype.70 Both macrophages and Th17 cells
are known to be involved inmultiple sclerosis pathology.1 The
H3-K27 demethylase Kdm6b (gene: KDM6B), also known as
Jmjd3, was one of the targets of erythrocyte-derived EV miR-
NAs that were decreased in multiple sclerosis. Demethylase
Jmjd3 was found to be crucial to the development of EAE.69
This further supports the involvement of erythrocyte-derived
EV miRNAs in multiple sclerosis pathology.
The erythrocyte miRNA validation study focussed largely
on the miR-183 cluster. While this cluster was not found to
be enriched in multiple sclerosis patient erythrocyte-derived
EVs compared to HCs, it may provide some insight as
to what is happening in the bone marrow during erythro-
cyte development. Erythrocytes are part of the myeloid lin-
eage, as are platelets and macrophages.11 With erythrocytes
being void of nuclei, miRNAs within them may have been
transcribed prior to maturation, where they are critical for
erythrocyte differentiation.30 The miR-183 cluster has been
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associated with early development of sensory organs, but also
implicated in pathologies such as cancer, neurological dis-
eases (neuropathic pain, nerve injury and neurodegenerative
disorders such as multiple-systems atrophy) and autoimmune
conditions (systemic lupus erythematosus and uveal autoim-
mune genetic syndromes).22 Considering the overlap between
miR-183 cluster targets and multiple sclerosis susceptibility
genes (Figure 5, Supporting Information File 5), its role in
autoimmunity may be affecting other cells of the myeloid lin-
eage during differentiation. While the overlap between miR-
183 cluster targets and multiple sclerosis susceptibility genes
suggests some involvement in the disease, further research is
required to determine the expression of miR-183 cluster miR-
NAs in myeloid precursor cells and its role in multiple sclero-
sis pathogenesis.
4.3 Conclusions and future directions
This study highlights the potential involvement of
erythrocyte-derived EV miRNAs as players in multiple
sclerosis pathology and the possibility of developing erythro-
cyte miRNAs into specific biomarkers for multiple sclerosis.
Nonetheless, there are limitations including the small sample
size, the use of separate cohorts for the study of erythrocyte
and erythrocyte-derived EV miRNAs and the creation of
EVs ex vivo. Future studies should aim to address some of
the limitations by isolating EVs from plasma, increasing
the power of the study to allow for the inclusion of male
patients and investigating the functionality of EV miRNAs.
This is the first study implicating erythrocyte-derived EV
miRNAs in multiple sclerosis. Potential links between these
miRNAs and pathological mechanisms demand further
investigation.
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